EPCAM_CHICK Ep-CAM ELISA tesk kit
- Known as:
- EPCAM_CHICK Ep-CAM Enzyme-linked immunosorbent assay test tesk reagent
- Catalog number:
- gen16461
- Product Quantity:
- 1
- Category:
- Peptides
- Supplier:
- Other suppliers
- Gene target:
- EPCAM_CHICK Ep-CAM ELISA tesk kit
Related genes to: EPCAM_CHICK Ep-CAM ELISA tesk kit
- Gene:
- EPCAM NIH gene
- Name:
- epithelial cell adhesion molecule
- Previous symbol:
- M4S1, MIC18, TACSTD1
- Synonyms:
- Ly74, TROP1, GA733-2, EGP34, EGP40, EGP-2, KSA, CD326, Ep-CAM, HEA125, KS1/4, MK-1, MH99, MOC31, 323/A3, 17-1A, TACST-1, CO-17A, ESA
- Chromosome:
- 2p21
- Locus Type:
- gene with protein product
- Date approved:
- 1995-10-02
- Date modifiied:
- 2019-04-23
Related products to: EPCAM_CHICK Ep-CAM ELISA tesk kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: EPCAM_CHICK Ep-CAM ELISA tesk kit
- Does vanillin, at concentrations relevant to maternal exposures during vaping, disrupt gastrulation-related processes in human embryonic stem cells (hESCs) by activating TRPV4 channels? - Source: PubMed
Publication date: 2026/08/12
Etemadi ShabnamTalbot Prue - Integrin α4β7 is a key adhesion receptor that mediates lymphocyte homing to the intestinal mucosa through interactions with MAdCAM-1, VCAM-1, and fibronectin, thereby playing a central role in gut immune surveillance and mucosal immunity. Emerging evidence has expanded its functional scope beyond intestinal homeostasis to encompass diverse inflammatory and metabolic diseases. This review systematically summarizes the structural characteristics, ligand interactions, and conformational regulation of α4β7, with an emphasis on its pathogenic roles in inflammatory bowel disease, cardiovascular diseases, diabetes, liver disorders, autoimmune diseases, gastrointestinal malignancies, HIV infection, asthma, and graft-versus-host disease. We discuss the underlying mechanisms, including lymphocyte trafficking, T cell co-stimulation, immune subset dysregulation, and crosstalk with the gut microbiota and epithelial barrier. In addition, we review the current landscape of α4β7-targeting therapeutics, including vedolizumab, etrolizumab, ontamalimab, and small-molecule antagonists, highlighting their clinical applications and limitations. By integrating recent mechanistic insights and therapeutic advances, this review provides a comprehensive framework for understanding the multifaceted roles of α4β7 and informs future strategies for targeting this integrin in disease. - Source: PubMed
Publication date: 2026/08/05
Chen YueChen YongZhang ZhiyuanTao MengxingGeng Chi - Circulating tumor cells (CTCs) are critical biomarkers for cancer prognosis and treatment monitoring, yet their detection remains challenging due to low abundance and phenotypic heterogeneity. Herein, we developed a dual-aptamer-conjugated electrochemical cytosensor using an in situ catalase (CAT)-encapsulated nanozyme CAT@Fe(SS)MOF-EpCAM/MUC1 (CMA) with a core-shell structure (64.8% catalase encapsulation efficiency) and magnetic nanoparticles Fe3O4-EpCAM/MUC1 (FA) for highly specific CTC capture. The CMA probe achieved 85.5% aptamer grafting efficiency and exhibited enhanced peroxidase (POD)-like activity through CAT-Fe(SS)MOF synergistic catalysis, significantly amplifying the differential pulse voltammetry (DPV) signal. The cytosensor achieved a detection limit of 2 cells/mL in 1 mL of whole blood, taking 95 min, with a wide linear range from 2 to 40 cells/mL. It demonstrated high specificity toward dual-antigen-expressing CTCs and showed promising clinical utility in discriminating lung cancer patients from healthy donors. The system demonstrated good anticoagulant properties, hemolysis rates of <5%, and IC50 values of 558 μg/mL (CMA) and >700 μg/mL (FA) for RAW264.7. This novel electrochemical cytosensor offers a portable and efficient platform for CTCs detection, thereby paving the way for its meaningful integration into clinical practice. - Source: PubMed
Publication date: 2026/08/09
Gan NaLiu PeiranZeng TingtingChen SiMo YazhiZhong JieSong YaliChen YuemeiWu Di - The tumor microenvironment (TME) critically regulates cancer progression by providing biochemical and biophysical cues that shape cellular behavior. However, how defined physical microenvironments govern cancer stemness and chemoresistance through mechanotransduction remains poorly understood. Here, we systematically engineered eight tumor-mimetic microenvironments by integrating serum, oxygen, and 3D compacted culture to investigate their effects on A549 non-small cell lung cancer cells. Among all conditions, cells cultured under 3D culture (PM4C) exhibited reduced cellular stiffness, enhanced expression of cancer stemness markers (EpCAM and CD44), and significantly increased resistance to cisplatin in both in vitro and nude mouse xenograft models. Transcriptomic analysis revealed that differentially expressed genes in the PM4C group were predominantly enriched in cell adhesion, mechanotransduction, stemness, and cisplatin resistance pathways. Metabolomic profiling further revealed a substantial accumulation of anaerobic metabolites associated with the maintenance of stemness. Mechanistically, the PM4C microenvironment remodeled matrix production, cell-ECM interactions, and cytoskeletal organization while inducing epigenetic reprogramming (reduced H3K9 acetylation), collectively promoting a stem-like and chemoresistant phenotype. These findings establish a direct mechanistic link between TME and cancer cell stemness, demonstrating that TME can reprogram stemness and drug responsiveness through mechano-epigenetic regulation. This work provides a mechanobiological framework for engineering physiologically relevant tumor organoids and offers new strategies for developing TME-targeted drugs and therapies. - Source: PubMed
Publication date: 2026/07/30
Zhang DuoduoLiu Yung-ChiangLi ChunchanXu YanshanCao YangLiu YinLiu XingjianHua YuyanWang Peng-Yuan - T cell-engaging antibody constructs (TCEs) have emerged as a potent modality to treat cancer and autoimmune diseases. Twelve TCEs have been approved by the FDA and EMA for the treatment of hematological malignancies or solid tumors. Despite the varying designs and binding properties, they all lead to robust single-agent efficacy and approvals in refractory or relapsed leukemia, lymphomas, multiple myeloma (MM), small cell lung cancer, EpCAM-expressing cancers or uveal melanoma. Where comparisons can be deduced, TCEs appear to achieve response rates like those obtained with CAR-T cell therapies. Given the success of the first generation of TCEs, considerable attempts are underway to further improve upon this modality. With the goal of expanding TCEs into other malignant and autoimmune indications, and to further enhance efficacy and improve safety, a multitude of novel TCEs are currently in preclinical and clinical development. Here we review the current approaches to developing next-generation TCEs that can widen the therapeutic index, address heterogeneous target expression, and thereby potentially improve efficacy and safety. - Source: PubMed
Publication date: 2026/07/22
Michaelson Jennifer SHenry Catherine CSauer KarstenBaeuerle Patrick A